Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx Medical posts revenue growth and margin gains, but losses persist and OEM sales decline.

What the company is saying

Apyx Medical emphasizes strong top-line growth, highlighting a 28% year-over-year increase in Surgical Aesthetics revenue to $12.4 million for Q2 2026. The company frames its narrative around operational momentum, improved gross profit, and narrowing net losses, using confident language to reaffirm full-year revenue guidance of $59.0–$60.0 million. Management draws attention to expanded FDA 510(k) clearance for the AYON Body Contouring System and clinical data claims, though these are described qualitatively without supporting figures. The announcement also spotlights marketing efforts, such as showcasing products at Miami Swim Week, to suggest growing brand awareness. Negative trends, such as the 12% decline in OEM revenue and increased operating expenses, are acknowledged but not emphasized. The overall tone is optimistic, focusing on realised financial improvements and anticipated benefits from new products and clinical milestones.

What the data suggests

Financial disclosures show total revenue rose to $13.9 million in Q2 2026, with Surgical Aesthetics as the primary driver. Gross profit increased 25% to $8.9 million, and gross margin improved to 63.9% from 62.3% year-over-year. Net loss attributable to stockholders narrowed to $3.2 million from $3.8 million, and adjusted EBITDA loss improved to $0.7 million from $2.0 million. Operating expenses rose to $10.7 million, up from $9.7 million, and net cash used in operating activities increased to $3.5 million from $1.2 million. OEM revenue declined 12% to $1.5 million, and FY2026 guidance projects further OEM contraction to $5.0 million from $7.5 million in 2025. The company ended the quarter with $27.6 million in cash and expects to remain cash-yielding through 2027. While financial trends are positive for core aesthetics, the lack of quantitative evidence for clinical and marketing claims limits independent validation of those growth drivers.

Analysis

The announcement presents a positive tone, highlighting revenue growth, improved gross profit, and narrowing losses. The majority of key claims are realised and supported by numerical evidence, such as revenue, gross margin, and adjusted EBITDA loss improvements. However, several claims regarding clinical data, regulatory milestones, and marketing events are presented without supporting quantitative evidence, which inflates the narrative relative to the measurable progress. The forward-looking ratio is moderate, with most claims being realised and only a few related to reaffirmed guidance and management projections. There is no indication of a large capital outlay or long-dated, uncertain returns; the execution distance for most benefits is immediate, as they relate to the reported quarter. The gap between narrative and evidence is most apparent in the qualitative claims about clinical and marketing achievements, which lack substantiating data.

Risk flags

• ●OEM revenue is declining, down 12% year-over-year in Q2 2026 and projected to fall further to $5.0 million for FY2026. This contraction reduces diversification and increases reliance on the Surgical Aesthetics segment, heightening vulnerability to demand shifts in that market.
• ●Operating expenses increased to $10.7 million from $9.7 million, and net cash used in operating activities rose to $3.5 million from $1.2 million. Rising costs and cash burn, despite improved margins, could pressure liquidity if revenue growth slows or if new product launches underperform.
• ●Several claims regarding clinical efficacy and marketing impact are unsubstantiated by numerical data. The absence of patient satisfaction scores, complication rates, or concrete event metrics makes it difficult to assess the true commercial potential or regulatory advantage of these initiatives.

Bottom line

Apyx Medical's Q2 2026 results confirm solid revenue growth and margin improvement, with the core Surgical Aesthetics segment up 28% and gross profit rising 25%. Losses are narrowing, but the company remains unprofitable and faces rising operating expenses and cash burn. OEM revenue is shrinking, increasing reliance on a single business line. Management's qualitative claims about clinical and marketing milestones lack supporting data, so their commercial impact is unclear. Investors should focus on whether the company can sustain revenue growth, control costs, and provide quantitative evidence for its clinical and marketing assertions. The key takeaway is that while financial momentum is positive, the investment case depends on future execution and more robust disclosure of non-financial achievements.

Announcement summary

(NASDAQ:APYX) Apyx Medical Corporation reported total revenue of $13.9 million in the second quarter of 2026, primarily driven by 28% growth in the Surgical Aesthetics segment. Surgical Aesthetics revenue increased to $12.4 million in the second quarter of 2026, compared with $9.7 million in the second quarter of 2025, while OEM revenue was approximately $1.5 million, representing a decrease of 12% from the same period last year. The company reported a net loss attributable to stockholders of $3.2 million in the second quarter of 2026, compared with a net loss of $3.8 million in the second quarter of 2025, and an adjusted EBITDA loss of $0.7 million compared to $2.0 million in the prior year period. Gross profit for the three months ended June 30, 2026, increased 25% to $8.9 million, with a gross margin of 63.9%. Operating expenses increased to $10.7 million for the three-month period ended June 30, 2026, compared with $9.7 million for the same period last year. The company reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million, with Surgical Aesthetics revenue expected to be in the range of $54.0 million to $55.0 million and OEM revenue expected to be approximately $5.0 million. As of June 30, 2026, the company had cash and cash equivalents of $27.6 million and management believes the company will yield cash through 2027.

Disagree with this article?